New Perspectives in the Management of Post-Surgical Macular Edema
Post-surgical macular edema is the most common cause of vision loss after phacoemulsification, and one of the main causes of reduced vision in patients undergoing other ocular surgery. At present, there are no reliable randomized clinical trials specifically designed to define the best
therapeutic approach, and little information is available regarding the treatment algorithm of acute or chronic forms. As a consequence, there is no agreement regarding the current management of post-surgical macular edema. Many therapeutic options have been proposed on the basis of the hypothesized
pathogenetic mechanism of post-surgical macular edema. New therapies for post-surgical macular edema include non-steroidal anti-flammatory drugs and intraocular steroid implants. Aim of the review is to update the current management of postsurgical macular edema, reporting on the most recent
therapeutic advances. In particular, we discuss the potential applications of recent patents with topical and intravitreal drugs.
Keywords: Corticosteroids; Fluorescein Angiography; Intravitreal Medications; Non-sterodal anti-inflammatory drugs; Optical Coherence Tomography; PSME; Post-surgical macular edema; Topical nepafenac formulations; steroids implants; sustained release corticosteroids
Document Type: Research Article
Publication date: 01 April 2012
- Recent Patents on Drug Delivery and Formulation publishes review articles by experts on recent patents on drug delivery and formulation. A selection of important and recent patents on drug delivery and formulation is also included in the journal. The journal is essential reading for all researchers involved in the fields of drug delivery and formulation.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content